Piper Sandler Assumes TCR2 Therapeutics (TCRR) at Overweight

November 18, 2021 4:16 PM EST
Get Alerts TCRR Hot Sheet
Price: $2.90 --0%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 12 | New: 10
Join SI Premium – FREE

Piper Sandler analyst Do Kim assumes coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Overweight rating and a price target of $26.00.


For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.


Shares of TCR2 Therapeutics closed at $6.60 yesterday.


You May Also Be Interested In





Related Categories

New Coverage